contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforias-change-negotiations-concluded-measures-aimed-to-enhance-companys-competitiveness-and-profitability

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Jeg har set alle videoerne fra i år om Aiforia, og det gav et godt indtryk af en selvsikker direktør og et firma, der hele tiden vinder kunder. Ser man på markedet, er det i en rigtig god position, og når grundlaget for kundevækst er skabt, så skulle man tro, det ville give overskud.

Svært at sige hvor stor en handel det ville være. Jukka sagde efter min mening, at 1 er sikker, og den anden går måske til næste år? Mange handler går under informationsgrænsen.

Jeg venter med interesse på, om der kommer en forretningsmeddelelse via Siemens Healthineers inden årets udgang. Jukka Tapaninen sagde i et interview offentliggjort den 12.11, at han forventede 1-2 handler inden årets udgang, og som en ret stor aktør ville man dog forvente, at der ville være tale om en ret god nyhed vedrørende Aiforia, forhåbentlig skrider det gunstigt frem.

Der var ingen større ændringer i november måneds ejerliste, Heller ikke SEB’s nominee-register fortsatte salgene (-200k oktober, -400k september). Tidligere på året i april flyttede ca. 1800k fra SEB’s register til Citibanks register baseret på tallene.  Redigering: Det skal dog tilføjes, at SEB’s salgsprojekt naturligvis stadig kan være i gang, eller det kan være afsluttet. Sandsynligvis kender det såkaldte ‘smart money’ situationen via deres købstjenester, men for os ‘bullere’ (investorer med en bullish holdning) efterlader mørk handel, alternative handelspladser og hemmelighederne ved nominee-registre – som børsherrerne roser for at effektivisere markedets funktion – situationen til spekulation. Antageligt har SEB dog aktier fra flere kunder i depot, og en stor kunde kan af en eller anden grund have ønsket at reducere (sin beholdning).                    Aiforia              Aiforia - Osakkeenomistajat    Aiforia on lääketieteen ohjelmistoyritys, joka tarjoaa patologeille ja tutkijoille kliinisissä, prekliinisissä ja akateemisissa laboratorioissa tehokkaan syväoppivan tekoälyohjelmiston.

(Jeg har gennemgået årets tråde og fandt ikke et svar, så jeg tør spørge…) Aiforia forventes ifølge analytikerne (Luiro, Rostedt) at foretage aktieemissioner i '26 og '27. Er der

NuWays videointerview, der ligesom Inderes følger Aiforia. Jeg har ikke set det endnu.

Interview med Jukka, hentet fra LinkedIn:                   Choose Paris Region              Aiforia launches its AI hub in Paris Region    Founded in 2013, Aiforia is a pioneering healthtech company transforming medical imaging through artificial intelligence and deep learning. Headquartered in Helsinki, the company has rapidly become a reference in AI-powered image analysis, supporting...

Aiforia Technologies

Aiforia’s change negotiations concluded - measures aimed to enhance company's competitiveness and profitabilityAiforia Technologies Plc, Press release, November 18, 2025 at 11:00 a.m. EETAs ...

Aiforia’s change negotiations concluded - measures aimed to enhance company's competitiveness and profitabilityAiforia Technologies Plc, Press release, November 18, 2025 at 11:00 a.m. EETAs part of broader financial adjustment measures, Aiforia Technologies announced on October 31, 2025, that it will start change negotiations. The objective of the financial adjustment measures is to improve the company's business competitiveness and profitability and to ensure the achievement of the company’s mid-term business targets.The change negotiations initiated on November 5, 2025, in accordance with the Act on Co-operation within Undertakings, covered 43 people in Aiforia Technologies Plc's Finnish operations. At the start of the negotiations, the company assessed that the planned changes would lead to the termination of the employment of a maximum of 9 people in Aiforia’s Finnish operations.As a result of the negotiations, the number of employees will be reduced by 8 people. In addition, Aiforia has initiated other measures to improve efficiency and to save costs. The personnel reductions, as well as the restructuring and streamlining of functions and tasks, are expected to deliver ongoing annual cost savings of approximately EUR 2.5 million, starting from the 2026 financial year. The measures will be implemented by the end of 2025.“The measures are part of a strategic shift where the focus is moving to stronger product commercialization. With the change negotiations, we have taken an important step towards a more efficient and competitive organization that supports our growth and profitability in the long term,” says the company's CEO, Jukka Tapaninen.Further inquiries Jukka Tapaninen, CEO, Aiforia Technologies Plc tel. +33 61 041 6686 <a href="https://investors.aiforia.com/">https://investors.aiforia.com/ </a>&nbsp;Certified Adviser&nbsp; UB Corporate Finance Ltd <a href="mailto:ubcf@unitedbankers.fi">ubcf@unitedbankers.fi</a>&nbsp;About Aiforia&nbsp;Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.&nbsp;Find out more at <a href="http://aiforia.com">www.aiforia.com</a>